← Back to Clinical Trials
Recruiting NCT04884620

NCT04884620 The 3rd COPENHAGEN Puberty Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04884620
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition Puberty
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2023-01-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 19 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2023-01-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The COPENHAGEN School Study is a combined cross-sectional and longitudinal study of healthy Danish school children. This study will by clinical examinations and withdrawal of blood samples investigate whether age of pubertal onset is continuing to decline in Denmark over the past 15 years. Furthermore, we will investigate the mechanism driving earlier onset of puberty and the long term health risks of extremely early puberty using Danish registry data

Eligibility Criteria

Inclusion Criteria: * Healthy children and adolescents Exclusion Criteria: * In case of acute disease, cancer, cancer therapy, or chronic disease (History of malignant disease, chemotherapy or radiation, cystic fibrosis, juvenile rheumatoid arthritis, systemic lupus erythematosus, sickle cell disease, thalassemia, chronic renal disease or known numerical chromosome aberration) * Non-Caucasian

Contact & Investigator

Central Contact

Anders Juul, PhD, DMSc

✉ anders.juul@regionh.dk

📞 +45 35 45 13 77

Principal Investigator

Anders Juul, PhD, DMSc

PRINCIPAL INVESTIGATOR

Rigshospitalet, Department of Growth and Reproduction

Frequently Asked Questions

Who can join the NCT04884620 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 19 Years, studying Puberty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04884620 currently recruiting?

Yes, NCT04884620 is actively recruiting participants. Contact the research team at anders.juul@regionh.dk for enrollment information.

Where is the NCT04884620 trial being conducted?

This trial is being conducted at Copenhagen, Denmark.

Who is sponsoring the NCT04884620 clinical trial?

NCT04884620 is sponsored by Rigshospitalet, Denmark. The principal investigator is Anders Juul, PhD, DMSc at Rigshospitalet, Department of Growth and Reproduction. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology